These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

167 related items for PubMed ID: 11181330

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.
    Sieber M, Bredenfeld H, Josting A, Reineke T, Rueffer U, Koch T, Naumann R, Boissevain F, Koch P, Worst P, Soekler M, Eich H, Müller-Hermelink HK, Franklin J, Paulus U, Wolf J, Engert A, Diehl V, German Hodgkin's Lymphoma Study Group.
    J Clin Oncol; 2003 May 01; 21(9):1734-9. PubMed ID: 12721249
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Monitoring bulky mediastinal disease with gallium-67, CT-scan and magnetic resonance imaging in Hodgkin's disease and high-grade non-Hodgkin's lymphoma.
    Zinzani PL, Zompatori M, Bendandi M, Battista G, Fanti S, Barbieri E, Gherlinzoni F, Rimondi MR, Frezza G, Pisi P, Merla E, Gozzetti A, Canini R, Monetti N, Babini L, Tura S.
    Leuk Lymphoma; 1996 Jun 01; 22(1-2):131-5. PubMed ID: 8724540
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Our experiences in treating patients with Hodgkin disease in the last decade].
    Simon Z, Keresztes K, Miltényi Z, Ress Z, Váróczy L, Vadász G, Gergely L, Illés A.
    Orv Hetil; 2007 Apr 15; 148(15):675-82. PubMed ID: 17416575
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Ifosfamide, epirubicin and etoposide (IEV) therapy in relapsed and refractory high-grade non-Hodgkin's lymphoma and Hodgkin's disease.
    Zinzani PL, Barbieri E, Visani G, Gherlinzoni F, Perini F, Neri S, Bendandi M, Ammendolia I, Salvucci M, Babini L.
    Haematologica; 1994 Apr 15; 79(6):508-12. PubMed ID: 7534744
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Controversy regarding the treatment of Hodgkin's disease].
    Balwierz W, Armata J.
    Pol Tyg Lek; 1989 Apr 03; 44(14):315-9. PubMed ID: 2482966
    [No Abstract] [Full Text] [Related]

  • 11. Radiotherapy for advanced Hodgkin's disease.
    Gupta T, Sanghavi V, Laskar S.
    N Engl J Med; 2003 Sep 18; 349(12):1187-8; author reply 1187-8. PubMed ID: 13679537
    [No Abstract] [Full Text] [Related]

  • 12. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group.
    Engert A, Schiller P, Josting A, Herrmann R, Koch P, Sieber M, Boissevain F, De Wit M, Mezger J, Duhmke E, Willich N, Muller RP, Schmidt BF, Renner H, Muller-Hermelink HK, Pfistner B, Wolf J, Hasenclever D, Loffler M, Diehl V, German Hodgkin's Lymphoma Study Group.
    J Clin Oncol; 2003 Oct 01; 21(19):3601-8. PubMed ID: 12913100
    [Abstract] [Full Text] [Related]

  • 13. Involved-field radiotherapy for advanced Hodgkin's lymphoma.
    Aleman BM, Raemaekers JM, Tirelli U, Bortolus R, van 't Veer MB, Lybeert ML, Keuning JJ, Carde P, Girinsky T, van der Maazen RW, Tomsic R, Vovk M, van Hoof A, Demeestere G, Lugtenburg PJ, Thomas J, Schroyens W, De Boeck K, Baars JW, Kluin-Nelemans JC, Carrie C, Aoudjhane M, Bron D, Eghbali H, Smit WG, Meerwaldt JH, Hagenbeek A, Pinna A, Henry-Amar M, European Organization for Research and Treatment of Cancer Lymphoma Group.
    N Engl J Med; 2003 Jun 12; 348(24):2396-406. PubMed ID: 12802025
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Advances in the chemotherapy of malignant lymphoma 1. Chemotherapy of Hodgkin's disease].
    Suon SZ.
    Zhonghua Nei Ke Za Zhi; 1985 Feb 12; 24(2):117-120, contd. PubMed ID: 2580675
    [No Abstract] [Full Text] [Related]

  • 16. [Use of risk-adapted programs of treatment of Hodgkin's disease in children and adolescents].
    Kuleva SA.
    Vopr Onkol; 2008 Feb 12; 54(6):768-70. PubMed ID: 19241857
    [Abstract] [Full Text] [Related]

  • 17. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy.
    Nachman JB, Sposto R, Herzog P, Gilchrist GS, Wolden SL, Thomson J, Kadin ME, Pattengale P, Davis PC, Hutchinson RJ, White K, Children's Cancer Group.
    J Clin Oncol; 2002 Sep 15; 20(18):3765-71. PubMed ID: 12228196
    [Abstract] [Full Text] [Related]

  • 18. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease.
    Fermé C, Eghbali H, Meerwaldt JH, Rieux C, Bosq J, Berger F, Girinsky T, Brice P, van't Veer MB, Walewski JA, Lederlin P, Tirelli U, Carde P, Van den Neste E, Gyan E, Monconduit M, Diviné M, Raemaekers JM, Salles G, Noordijk EM, Creemers GJ, Gabarre J, Hagenbeek A, Reman O, Blanc M, Thomas J, Vié B, Kluin-Nelemans JC, Viseu F, Baars JW, Poortmans P, Lugtenburg PJ, Carrie C, Jaubert J, Henry-Amar M, EORTC-GELA H8 Trial.
    N Engl J Med; 2007 Nov 08; 357(19):1916-27. PubMed ID: 17989384
    [Abstract] [Full Text] [Related]

  • 19. ABMT recommended for relapsed Hodgkin's disease, but better overall survival not yet proved.
    Oncology (Williston Park); 1996 Apr 08; 10(4):593-4. PubMed ID: 8723294
    [No Abstract] [Full Text] [Related]

  • 20. [Hodgkin's lymphoma and radiotherapy].
    Datsenko PV, Panshin GA.
    Vopr Onkol; 2015 Apr 08; 61(1):45-51. PubMed ID: 26016145
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.